LRMR

Larimar Therapeutics, Inc.

9.62 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Larimar Therapeutics, Inc. stock is up 22.08% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 May 17:37 17 May, 2024 7.50 CALL 6984 7087

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia.

  • JP Morgan
    Fri May 31, 11:44
    buy
    confirm
  • Citigroup
    Wed May 22, 13:48
    buy
    confirm
  • JP Morgan
    Tue May 21, 12:35
    buy
    confirm